Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Single Dose, Two-way Cross-Over Study to Investigate the Relative Bioavailability of Capecitabine in Rapid Disintegrating Tablets (RDT) Versus the Commercial Xeloda® Tablets Following Oral Administrations in Adult Patients With Solid Tumours
Conditions
Interventions
capecitabine RTD
capecitabine [Xeloda]
+1 more
Locations
8
Australia
Adelaide, South Australia, Australia
Nedlands, Western Australia, Australia
Christchurch, New Zealand
Grafton, New Zealand
Glasgow, United Kingdom
Leeds, United Kingdom
Start Date
May 1, 2012
Primary Completion Date
October 1, 2012
Completion Date
October 1, 2012
Last Updated
November 2, 2016
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions